Adrenocortical carcinoma risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{AAM}} | {{CMG}} {{AE}} {{AAM}} | ||
==Overview== | ==Overview== | ||
The most potent risk factor in the development of adrenocortical cancer is [[TP53| TP53 mutation]]. | |||
==Common Risk Factors== | ==Common Risk Factors== | ||
Families with [[Li-Fraumeni syndrome]] have increased risk. | *Families with [[Li-Fraumeni syndrome]] (TP53 mutation) have increased risk for adrenocortical cancer. | ||
==References== | ==References== | ||
Revision as of 17:22, 25 August 2015
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma risk factors On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma risk factors |
|
Risk calculators and risk factors for Adrenocortical carcinoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Overview
The most potent risk factor in the development of adrenocortical cancer is TP53 mutation.
Common Risk Factors
- Families with Li-Fraumeni syndrome (TP53 mutation) have increased risk for adrenocortical cancer.